You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

20-010

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Geriatric Syndrome Trial in Indianapolis (TeleGRACE)

Terminated
  • Geriatric Syndrome
  • TeleGRACE
  • Indianapolis, Indiana
    Richard L. Roudebush VA Medical Center, Indianapolis, IN
May 9, 2022

Safety Evaluation of GamCath HighFlow Dolphin Protect Catheter

Enrolling by invitation
  • AKI - Acute Kidney Injury
  • +3 more
  • Vascular access catheter to support dialysis or CRRT
  • Lublin, Poland
  • +1 more
Jun 2, 2023

Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK)

Recruiting
  • Common Cold
  • Allergy
  • Healsea® Children
  • Conventional therapies for common cold
  • Białystok, Poland
  • +14 more
Mar 11, 2022

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma Trial in Japan (epcoritamab

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • epcoritamab (monotherapy)
  • +5 more
  • Chuo Ku, Japan
  • +19 more
Nov 22, 2022

Sickle Cell Disease (SCD) Trial in Worldwide (Crizanlizuamb, Standard of Care)

Active, not recruiting
  • Sickle Cell Disease (SCD)
  • Birmingham, Alabama
  • +24 more
Jan 12, 2023

Pneumococcal Disease Trial in Worldwide (20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine)

Active, not recruiting
  • Pneumococcal Disease
  • 20-valent pneumococcal conjugate vaccine
  • 13-valent pneumococcal conjugate vaccine
  • Nedlands, Western Australia, Australia
  • +63 more
Nov 3, 2022

Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL Trial in Worldwide (VGX-3100, Placebo,

Completed
  • Cervical Dysplasia
  • +2 more
  • VGX-3100
  • +2 more
  • Tucson, Arizona
  • +52 more
Oct 13, 2022

Classical Hodgkin Lymphoma Trial in Guangzhou (Zimberelimab 240mg)

Recruiting
  • Classical Hodgkin Lymphoma
  • Zimberelimab 240mg
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-Sen University Cancer Ce
Jun 15, 2023

Agitation in Patients With Dementia of the Alzheimer's Type Trial in Worldwide (AVP-786, Placebo)

Recruiting
  • Agitation in Patients With Dementia of the Alzheimer's Type
  • Birmingham, Alabama
  • +82 more
Aug 23, 2022

Relapsed/Refractory Diffuse Large B-cell Lymphoma Trial in China (ATG-010 and ATG-008)

Recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma
  • ATG-010 and ATG-008
  • Chongqing, Chongqing, China
  • +5 more
Sep 2, 2022

Idiopathic Hypersomnia, Excessive Daytime Sleepiness Trial in United States (pitolisant)

Enrolling by invitation
  • Idiopathic Hypersomnia
  • Excessive Daytime Sleepiness
  • Peoria, Arizona
  • +57 more
Nov 10, 2022

Relapse/Refractory Multiple Myeloma Trial in China (ATG-010)

Completed
  • Relapse/Refractory Multiple Myeloma
  • Beijing, Beijing, China
  • +16 more
Jul 27, 2022

Relapsed or Refractory Multiple Myeloma Trial in China (SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone))

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • SVd (Selinexor+Bortezomib+dexamethasone)
  • Vd (Bortezomib+dexamethasone)
  • Hefei, Anhui, China
  • +33 more
Aug 14, 2022

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Trial (Nemtabrutinib, Venetoclax,

Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +5 more
  • (no location specified)
Jul 21, 2023

Low Back Pain Trial in Worldwide (Matching Placebo, Low Dose GRT6005, Medium Dose GRT6005)

Completed
  • Low Back Pain
  • Matching Placebo
  • +4 more
  • Senftenberg, Austria
  • +78 more
Jul 13, 2021

Dyslipidemias Trial in Korea, Republic of (Atorvastatin)

Completed
Has Results
  • Dyslipidemias
  • Daegu, Korea, Korea, Republic of
  • +19 more
Feb 17, 2021

Thalassemia Trial in Canada, United Kingdom, United States (AG-348)

Active, not recruiting
Has Results
  • Thalassemia
  • Oakland, California
  • +3 more
Jan 26, 2023

Melanoma Trial in Nedlands, Haifa, Jerusalem (Pembrolizumab/Vibostolimab, Pembrolizumab)

Recruiting
  • Melanoma
  • Pembrolizumab/Vibostolimab
  • Pembrolizumab
  • Nedlands, Western Australia, Australia
  • +2 more
Jan 31, 2023

Endometriosis Trial in Worldwide (Relugolix, Estradiol/norethindrone acetate)

Active, not recruiting
  • Endometriosis
  • Andalusia, Alabama
  • +168 more
May 31, 2022

Respiratory Syncytial Virus Infections Trial (RSVPreF3 vaccine, Control)

Not yet recruiting
  • Respiratory Syncytial Virus Infections
  • RSVPreF3 vaccine
  • Control
  • (no location specified)
Jan 20, 2023

Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)

Not yet recruiting
  • Solid Tumor
  • +2 more
  • favezelimab/pembrolizumab
  • +2 more
  • (no location specified)
Sep 7, 2023

SARS-CoV-2 Infection, COVID-19 Trial in United Kingdom (SARS-CoV-2 rS/Matrix M1-Adjuvant, Placebo, Licensed seasonal influenza

Active, not recruiting
  • SARS-CoV-2 Infection
  • COVID-19
  • SARS-CoV-2 rS/Matrix M1-Adjuvant
  • +2 more
  • Belfast, Antrim, United Kingdom
  • +32 more
Oct 19, 2022

Prostatic Tumors Trial in Worldwide (Pembrolizumab, Olaparib, Abiraterone acetate)

Active, not recruiting
  • Prostatic Neoplasms
  • Pembrolizumab
  • +4 more
  • Fullerton, California
  • +192 more
Oct 17, 2022

Obesity Trial in Worldwide (Semaglutide, Placebo)

Recruiting
  • Obesity
  • Birmingham, Alabama
  • +106 more
Jan 24, 2023

Diabetes, Type 2 Trial in Tanta, Shibin Al Kawm (Nitazoxanide)

Recruiting
  • Diabetes Mellitus, Type 2
  • Tanta, El-Gharbia, Egypt
  • +1 more
Aug 21, 2023